ANI PHARMACEUTICALS, INC Operating Lease, Right-of-Use Asset, Amortization Expense
ANI PHARMACEUTICALS, INC (ANIP) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $909.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $456.00K, a 15.74% increase year-over-year.
- ANI PHARMACEUTICALS, INC operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $453.00K, a 0.22% increase year-over-year.
- ANI PHARMACEUTICALS, INC operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $555.00K, a 41.58% increase year-over-year.
- ANI PHARMACEUTICALS, INC operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $358.00K, a 6.77% decline year-over-year.
- ANI PHARMACEUTICALS, INC operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.76M, a 15.27% increase from fiscal 2024.
- ANI PHARMACEUTICALS, INC operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.53M, a 20.25% increase from fiscal 2023.
- ANI PHARMACEUTICALS, INC operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.27M.
- ANI PHARMACEUTICALS, INC operating lease, right-of-use asset, amortization expense for fiscal 2022 was $0.00.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $456.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $909.00K 10-Q · filed 2026-08-07 | $1.46M derived: sum of 3 quarters · filed 2026-08-07 | $1.82M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $453.00K 10-Q · filed 2026-05-08 | $1.01M derived: sum of 2 quarters · filed 2026-05-08 | $1.37M derived: sum of 3 quarters · filed 2026-05-08 | $1.76M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $555.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $913.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.31M derived: sum of 3 quarters · filed 2026-08-07 | $1.76M 10-K · filed 2026-02-27 |
| 2025-09-30 | $358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $752.00K derived: sum of 2 quarters · filed 2026-08-07 | $1.20M 10-Q · filed 2025-11-07 | $1.60M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $394.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $846.00K 10-Q · filed 2026-08-07 | $1.24M derived: sum of 3 quarters · filed 2026-08-07 | $1.62M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $452.00K 10-Q · filed 2026-05-08 | $844.00K derived: sum of 2 quarters · filed 2026-05-08 | $1.23M derived: sum of 3 quarters · filed 2026-05-08 | $1.60M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $392.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $776.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.15M derived: sum of 3 quarters · filed 2026-02-27 | $1.53M 10-K · filed 2026-02-27 |
| 2024-09-30 | $384.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $761.00K derived: sum of 2 quarters · filed 2025-11-07 | $1.13M 10-Q · filed 2025-11-07 | $1.51M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $377.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $750.00K 10-Q · filed 2025-08-08 | $1.13M derived: sum of 3 quarters · filed 2026-02-27 | $1.96M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $373.00K 10-Q · filed 2025-05-09 | $754.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.58M derived: sum of 3 quarters · filed 2026-02-27 | $1.64M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $381.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.21M derived: sum of 2 quarters · filed 2026-02-27 | $1.27M derived: sum of 3 quarters · filed 2026-02-27 | $1.27M 10-K · filed 2026-02-27 |
| 2023-09-30 | $827.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $888.00K derived: sum of 2 quarters · filed 2024-11-08 | $888.00K 10-Q · filed 2024-11-08 | $888.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $61.00K 10-Q · filed 2024-08-06 | $61.00K derived: sum of 3 quarters · filed 2025-02-28 | $61.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 derived: sum of 3 quarters · filed 2025-02-28 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |